# Dostarlimab and Cobolimab in Advanced Cervical Cancer

> **NCT06238635** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Meghan Shea** · enrollment: 66 (estimated)

## Conditions studied

- Cervical Cancer
- Advanced Cervical Carcinoma
- Metastatic Cervical Cancer
- Metastatic Cervical Carcinoma
- Recurrent Cervical Carcinoma

## Interventions

- **DRUG:** Dostarlimab
- **DRUG:** Cobolimab

## Key facts

- **NCT ID:** NCT06238635
- **Lead sponsor:** Meghan Shea
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-11
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-07-15
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06238635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06238635, "Dostarlimab and Cobolimab in Advanced Cervical Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06238635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*